{"nctId":"NCT04270682","briefTitle":"Study to Evaluate Patients With Cerebrotendinous Xanthomatosis (RESTORE)","startDateStruct":{"date":"2020-01-31","type":"ACTUAL"},"conditions":["CTX"],"count":19,"armGroups":[{"label":"Adult Cohort","type":"EXPERIMENTAL","interventionNames":["Drug: Blinded CDCA 250 mg TID","Drug: Placebo","Drug: Open-Label CDCA 250 mg TID","Drug: Rescue Medication CDCA 250 mg TID"]},{"label":"Pediatric Cohort","type":"EXPERIMENTAL","interventionNames":["Drug: CDCA Weight-Based Dose TID"]}],"interventions":[{"name":"Blinded CDCA 250 mg TID","otherNames":[]},{"name":"Placebo","otherNames":[]},{"name":"Open-Label CDCA 250 mg TID","otherNames":[]},{"name":"Rescue Medication CDCA 250 mg TID","otherNames":[]},{"name":"CDCA Weight-Based Dose TID","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. Male or female at least 1 month or older at screening.\n2. Clinical diagnosis of CTX with biochemical confirmation.\n3. Women of childbearing potential must agree to the use of one highly reliable method of contraception during the study, plus one additional barrier method during sexual activity.\n4. Males must be surgically sterile, or males and their sexual partners must together agree to use medically accepted methods of contraception that are considered highly reliable during the course of the study.\n\nExclusion Criteria:\n\n1. Genetic testing does not confirm CTX.\n2. Malabsorption disorder or confounding inflammatory gastrointestinal condition (for example, irritable bowel syndrome).\n3. Documented history of heart failure.\n4. Treated with medications which impact bile acid absorption such as bile acid sequestering agents (eg, cholestyramine, colestipol, aluminum-based antacids.\n5. Treated with cholic acid medication.\n6. Female patient who is pregnant, plans to become pregnant during the course of the study, or is breastfeeding.\n7. Positive at screening for the human immunodeficiency virus (HIV) or markers indicating acute or chronic hepatitis B infection or hepatitis C infection.","healthyVolunteers":false,"sex":"ALL","minimumAge":"1 Month","stdAges":["CHILD","ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change From Baseline in Urine 23S-Pentol During the Two Double-Blind Periods","description":"Primary Analysis of Change from Baseline in Urine 23S-Pentol (Natural Log-Transformed) during the Two Double-blind Periods- Paired T-test","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7.18","spread":"0.797"},{"groupId":"OG001","value":"6.96","spread":"1.076"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.45","spread":"0.675"},{"groupId":"OG001","value":"10.34","spread":"0.788"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.20","spread":"0.732"},{"groupId":"OG001","value":"3.38","spread":"1.111"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline Plasma Cholestanol During the Two Double-Blind Periods","description":"Primary Analysis of Change from Baseline Plasma Cholestanol (Natural Log-transformed) at the End of the Two Double-Blind Periods- Paired T-test","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.13","spread":"0.791"},{"groupId":"OG001","value":"1.14","spread":"0.534"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.10","spread":"0.728"},{"groupId":"OG001","value":"1.88","spread":"0"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.12","spread":"0.542"},{"groupId":"OG001","value":"0.75","spread":"0.865"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline Plasma 7αC4 During the Two Double-Blind Periods","description":"Primary Analysis of Change from Baseline Plasma 7αC4 (Natural Log-Transformed) During the Two Double-Blind Periods","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.02","spread":"0.519"},{"groupId":"OG001","value":"4.00","spread":"0.526"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.97","spread":"0.572"},{"groupId":"OG001","value":"7.60","spread":"0.511"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.08","spread":"0.717"},{"groupId":"OG001","value":"3.60","spread":"0.742"}]}]}]},{"type":"SECONDARY","title":"Proportion of Participants Who Received Rescue Treatment During Two Double-Blind Periods","description":"Proportion of Participants Who Received Rescue Treatment during Two Double-Blind Periods - Prescott's Method","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"8","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":13},"commonTop":["Diarrhea","Constipation","Fatigue","Gait Disturbance","Fall"]}}}